Md Raihan Siddique’s Post

Looking for a modern multiplex panel to optimize your cancer research? The Human Tumor Biomarker Panel from Bio-Techne is coming soon, allowing researchers to analyze 28 critical cancer biomarkers including CA125, PSA Total, and Neuro-specific Enolase using just 50 µL of sample. Read more in the June edition of our free xMAP® Resource Round-Up newsletter, now available in your inbox. Subscribe now to receive monthly xMAP® updates, news, and product offerings: https://hubs.li/Q02FgN5G0 #cancerresearch #xMAP #multiplexing

Are you attending the World Conference on Lung Cancer (#WCLC24) this week? 🔬💊 Then make sure to attend the presentation by our scientific collaborator Angelica Rigutto, PhD from Université de Fribourg - Universität Freiburg tomorrow about #biomarkers discovery in the Phase 2 SAKK 17/18 ORIGIN trial in patients with non-small cell lung cancer (#NSCLC) who progressed on #immunotherapy. Our #TrueDiscovery® platform was used for ultra-deep plasma proteome profiling, revealing novel predictive markers of response. 👉Find the abstract and session details here: https://lnkd.in/dZhk6vqS Also, don't miss the opportunity to meet our scientific experts, Valesca Anschau Ph.D. and Christian Cizek, to explore how our #proteomics research services can support your #LungCancer research. 👋 #Proteomics #PlasmaProteomics #Oncology #CancerResearch #DrugDevelopment

🔬 ETH Zurich's latest research led by Andreas Moor has revealed a pivotal interaction between proteins on colorectal cancer cells and liver cells that could significantly advance our fight against deadly metastases. By understanding the "molecular handshake" that allows cancer cells to take root in the liver, the team opens the door to potential treatments aimed at preventing the spread of cancer. This discovery not only shifts the landscape of cancer treatment but could lead to groundbreaking therapies to halt metastases before they start. #CancerResearch #ETHZurich #HealthInnovation #Oncology Read more: https://lnkd.in/eCRgdh3y

17 years ago today, a Japanese team led by Dr. Hiroyuki Mano published the first study about the ALK-positive mutation in lung cancer. This significant discovery has led to targeted treatments, improving outcomes for current and future ALK+ patients. We're deeply grateful for the doctors, researchers, and patients, past and present, who have made this progress possible. Image features a micrograph showing ALK-positive lung adenocarcinoma. Hematoxylin and Eosin (H&E) stain; this staining technique helps differentiate between different components of the tissue, making it easier to identify abnormalities, such as cancer cells. #ALKPositive #alkpositivelungcancer #LungCancer #NSCLC

💥Happy to share our latest publication 💥 our review article ""Methionine restriction for cancer therapy:From pre clinical studies to clinical trials " has been published in the Scopus- indexed journal cancer pathogenesis and Therapeutics by the Chinese medical Association (CMA). This work highlights the crucial role of Methionine in cancer biology and the potential of Methionine restriction as a therapeutic strategy. I would like to extend my gratitude to Bandaru Nagaraju sir for his valuable supervision and guidance throughout this journey. looking forward to contributing more to the evolving field of cancer research. 💫 #KLU #Reaserch #cancertherapy #pharmD #Scopusindex #cancerpathogenesis #cancer #preclinicalstuides

We’re driven by science to change the way cancer is treated by pursuing novel small molecules that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK and FAK inhibition. If you are attending the International Gynecologic Cancer Society (IGCS) annual meeting, stop by our booth to learn more about our clinical research in this area. #IGSC2024 #KRAS #Cancerresearch #gynonc #VerastemOnc

🔈Research news 🔬 New research reveals a key vulnerability in LKB1-deficient non-small cell lung cancer (NSCLC), which is one of the deadliest forms of cancer and affects about 30% of cases all patients suffering from NSCLC. With contributions from professor Jiri Bartek, head of the Genome Integrity Group at the Danish Cancer Institute, a team of international scientists used zebrafish and human lung organoid models to screen for compounds that target these tumours. They identified two kinase inhibitors, Piceatannol and Tyrphostin 23, that show promise for more effective treatments. #cancer #cancerresearch #science #lungcancer

New research from Memorial Sloan Kettering Cancer Center (MSK) investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution. Learn more: https://lnkd.in/eUrqAzEc

Read article: https://lnkd.in/gXQ-x6PM. Sensitive methods for measuring circulating tumor DNA (ctDNA) have empowered researchers to explore noninvasive approaches for detecting residual traces of cancer post intervention, known as molecular residual disease (MRD). Recently The Scientist had a Q&A with Isaac Garcia-Murillas of The Institute of Cancer Research in London to discuss new insights into the relationship between MRD and cancer progression, the way clinical trials are evolving to incorporate ctDNA analysis, and how ddPCR technology is driving progress in the field of oncology research. Learn more about detecting ctDNA for cancer research with ddPCR technologies: https://lnkd.in/gsXAHS4W #LiquidBiopsy #ddPCR #BreastCancer

"Picking the PI3K Mutations: Paving the Way for Precision Medicine in Breast Cancer" A recent study published in Nature Scientific Reports uncovers the role of PIK3CA mutations in endocrine-resistant breast cancer. These findings shed light on potential therapeutic targets and pave the way for personalized treatments. Discover the full study https://lnkd.in/dDHc3HfD #BreastCancerResearch #Genomics #CancerTreatment #PIK3CA #ScientificReports #MedicalResearch